A Survey of American Psychiatrists Concerning Medication Prior Authorization Requirements.
Adult
Aged
Fees, Pharmaceutical
Female
Health Expenditures
/ trends
Humans
Insurance, Pharmaceutical Services
/ economics
Insurance, Psychiatric
/ economics
Job Satisfaction
Logistic Models
Male
Medicaid
Middle Aged
Multivariate Analysis
Prior Authorization
/ economics
Psychiatry
/ organization & administration
Psychotropic Drugs
/ economics
Surveys and Questionnaires
United States
Journal
The Journal of nervous and mental disease
ISSN: 1539-736X
Titre abrégé: J Nerv Ment Dis
Pays: United States
ID NLM: 0375402
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
entrez:
1
7
2020
pubmed:
1
7
2020
medline:
25
3
2021
Statut:
ppublish
Résumé
This study examined opinions of American psychiatrists regarding prior authorization (PA) requirements for third-party payer coverage of medications and quantified perceived impact of these requirements on clinical practice. One thousand selected psychiatrist members of the American Psychiatric Association were invited to participate in a survey. Response rate was 33.1%. Respondents predominantly believed the obligation to obtain PA reduces job satisfaction and negatively impacts patient care. A total of 59.9% of respondents reported employing either diagnosis modification or falsification of previous medication trials at least occasionally in order to obtain PA. A total of 66.6% refrained at least occasionally from prescribing preferred medications due to PA requirement or expectation of one. On multivariate analysis, risk factors for refraining at higher frequency included seeing 300 or more patients in the previous 3 months, engaging more frequently in diagnosis modification, and reporting increased perception that obtaining PA reduces time for patient care.
Identifiants
pubmed: 32604163
doi: 10.1097/NMD.0000000000001171
pii: 00005053-202007000-00007
doi:
Substances chimiques
Psychotropic Drugs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
566-573Références
Adams AS, Zhang F, LeCates RF, Graves AJ, Ross-Degnan D, Gilden D, McLaughlin TJ, Lu C, Trinacty CM, Soumerai SB (2009) Prior authorization for antidepressants in Medicaid: Effects among disabled dual enrollees. Arch Intern Med. 169:750–756.
American Medical Association (2015) Prior authorization: The current landscape. Chicago, IL: American Medical Association Publishing. Available at: https://edhub.ama-assn.org/data/multimedia/10.1001ama.2018.0080supp2.pdf. Accessed March 13, 2020.
American Medical Association (2017) Health care coalition calls for prior authorization reform. Available at: https://www.ama-assn.org/press-center/press-releases/health-care-coalition-calls-prior-authorization-reform.
Berlin J (2019) TMA Pushes for Prior Authorization Limits, Clarity. Texas Med Assocation Website. Available at: https://www.texmed.org/TexasMedicineDetail.aspx?id=50427. Accessed December 8, 2019.
Brown CM, Richards K, Rascati KL, Gavaza P, Corbell Z, Zachry W, Phillips GA (2008) Effects of a psychotherapeutic drug prior authorization (PA) requirement on patients and providers: A providers' perspective. Adm Policy Ment Health. 35:181–188.
Butcher L (2017) Seeing it from both sides now. Manag Care. 26:18–24.
Centers for Medicare & Medicaid Services (2019) CMS proposes to update e-prescribing standards to reduce provider burden and expedite access to needed medications. CMS.gov. Available at: https://www.cms.gov/newsroom/press-releases/cms-proposes-update-e-prescribing-standards-reduce-provider-burden-and-expedite-access-needed. Accessed December 8, 2019.
Desai NR, Shrank WH, Fischer MA, Avorn J, Liberman JN, Schneeweiss S, Pakes J, Brennan TA, Choudhry NK (2012) Patterns of medication initiation in newly diagnosed diabetes mellitus: Quality and cost implications. Am J Med. 125:302.e1–302.e7.
Freeman VG, Rathore SS, Weinfurt KP, Schulman KA, Sulmasy DP (1999) Lying for patients: Physician deception of third-party payers. Arch Intern Med. 159:2263–2270.
Kahan NR, Waitman D-A, Chinitz DP (2016) Revealed opportunism: How physicians “game” prior authorization protocols until they are rescinded. Am Health Drug Benefits. 9:304–311.
Kumar S (2007) Burnout in psychiatrists. World Psychiatry. 6:186–189.
Lu C, Adams A (2011) Association between prior authorization for psychiatric medications and use of health services among Medicaid patients with bipolar disorder. Psychiatr Serv. 62:186–193.
Medicaid and CHIP Payment and Access Commission (2015) June 2015 report to Congress on Medicaid and CHIP- Chapter 5 Use of psychotropic medications among medicaid beneficiaries. Available at: https://www.macpac.gov/publication/use-of-psychotropic-medications-among-medicaid-beneficiaries/. Accessed March 13, 2020.
Medscape (2019) Medscape National Physician Burnout, Depression and Suicide Report 2019. Available at: https://www.medscape.com/slideshow/2019-lifestyle-burnout-depression-6011056. Accessed March 13, 2020.
Morra D, Nicholson S, Levinson W, Gans DN, Hammons T, Casalino LP (2011) US physician practices versus Canadians: Spending nearly four times as much money interacting with payers. Health Aff (Millwood). 30:1443–1450.
Rajagopalan K, Hassan M, Boswell K, Sarnes E, Meyer K, Grossman F (2016) Review of outcomes associated with restricted access to atypical antipsychotics. Am J Manag Care. 22:e208–e214.
Reinke T (2012) Prior authorization for safety, not just for economy. Manag Care. 21:33–35.
Roehrig C (2016) Mental disorders top the list of the most costly conditions in the United States: $201 billion. Health Aff (Millwood). 35:1130–1135.
Smith M, Sprecher B (2017) Pharmacy communications with physician offices to clarify prescriptions. J Am Pharm Assoc. 57:178–182.
Starner CI, Fenrick B, Coleman J, Wickersham P, Gleason PP (2012) Rosiglitazone prior authorization safety policy: A cohort study. J Manag Care Pharm. 18:225–233.
Vogt WB, Joyce G, Xia J, Dirani R, Wan G, Goldman DP (2011) Medicaid cost control measures aimed at second-generation antipsychotics led to less use of all antipsychotics. Health Aff (Millwood). 30:2346–2354.
Wegner SE, Trygstad TK, Dobson LA Jr., Lawrence WW Jr., Steiner BD (2009) A physician-friendly alternative to prior authorization for prescription drugs. Am J Manag Care. 15:e115–e122.
West JC, Wilk JE, Rae DS, Muszynski IL, Rubio-Stipec M, Alter CL, Sanders KE, Crystal S, Regier DA (2010) First-year Medicare part D prescription drug benefits: Medication access and continuity among dual eligible psychiatric patients. J Clin Psychiatry. 71:400–410.